Canada's Monument Mining FY revenue jumps on higher gold sales, prices
Reuters2026/09/30 04:17
Overview
Canada gold miner's fiscal 2026 revenue rose sharply on higher gold sales and prices
Net earnings and EPS increased year-over-year, reflecting improved financial position
Outlook
Company did not provide specific guidance for the current quarter or fiscal year in the press release
Result Drivers
HIGHER GOLD PRICES AND SALES - Co attributed increased revenue and gross margin to higher gold sales volumes and stronger realized gold prices
HIGHER MINING COSTS - Co said cash cost per ounce increased due to deeper mining, higher royalty rates and payments, partially offset by improved recovery rates
EXPLORATION AND DEVELOPMENT - Extensive exploration and mine development at Selinsing targeted resource growth and mine life extension
Company press release: ID:nGNX5m9DwQ
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
FY Revenue |
|
$165.7 mln |
|
FY Basic EPS |
|
$0.20 |
|
Reuters Recommended Reads
Sept 28 - Northern Star rejects Gold Fields' $27 billion bid to create world's No.2 gold miner
Sept 27 - Barrick Mining reaches deal with unions at Mali gold mine, easing strike threat
Sept 29 - Kazakhstan-focused miner Altyngold's H1 profit jumps on higher gold prices
For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact [email protected].
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment
According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.
GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions
Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.
BUZZ-3M India shares fall to 19-month low due to quarterly profit decline
Anthropic (ANT.US) to launch IPO roadshow next week, valuation may shrink from 1.5 trillion dollars to 1 trillion dollars! The AI capital feast faces a test.
After the AI sell-off, major investors are questioning whether Anthropic can go public at a $1.5 trillion valuation, or if it will be reduced to around $1 trillion. Fundraising may also decrease from $100 billion to $80 billion.
Crypto prices
More
